BridgeBio Pharma announced FDA acceptance of its regulatory filing for infigratinib, an oral drug to treat achondroplasia in children, with priority review and a decision expected by February 4, 2027. The drug demonstrated 2.1 cm/year greater height growth than placebo in Phase III trials. If approved, it would be the first oral therapy for achondroplasia, differentiating it from injectable competitors. BridgeBio also has two other near-term regulatory catalysts (BBP-418 and encaleret) that could diversify its revenue beyond its current marketed product Attruby.

BioMarin Pharmaceutical announced it is discontinuing development of Voxzogo for Noonan syndrome due to study feasibility and treatment landscape concerns, though not due to safety or efficacy issues. Despite this setback, Voxzogo generated $472 million in first-half 2026 sales (up 9% YoY) and is on track to achieve blockbuster status with expected 2026 sales of $1.00-$1.05 billion. The drug faces increasing competition from Ascendis Pharma's Yuviwel and BridgeBio's infigratinib, though BioMarin secured a royalty-bearing settlement with Ascendis.

Ascendis Pharma A/S announced that its Board of Directors has authorized a $400 million share repurchase program. The company will execute purchases through various methods including open market transactions and accelerated share repurchase agreements, with timing and amounts determined by market conditions and share price.

BioMarin settled a patent dispute with Ascendis Pharma over the achondroplasia drug Yuviwel, converting a competitive threat into a royalty stream. Under the agreement, BioMarin will receive 20% royalties on U.S. Yuviwel sales and 18% in the EU, Brazil, and South Korea through May 2030. While this monetizes competition, BioMarin still faces market pressure from Yuviwel and potential future competitors like BridgeBio's infigratinib.

The pharmaceutical industry is experiencing a record-breaking M&A wave in 2026, driven by looming patent cliffs worth $300 billion in annual revenue, FDA regulatory improvements for rare diseases, and the need to diversify portfolios. Companies are making strategic bolt-on acquisitions of late-stage drug candidates rather than massive mergers. While some firms like Eli Lilly are well-positioned, others like Merck and Pfizer face near-term patent expirations that could impact revenue significantly.

Ascendis Pharma reported positive five-year results from its PaTH Forward trial for TransCon PTH (YORVIPATH), showing sustained efficacy and safety in treating adult hypoparathyroidism. The therapy demonstrated that 82% of patients met composite response endpoints, with 88% maintaining normal calcium levels and 96% achieving independence from active vitamin D therapy. The drug showed durable kidney benefits and a consistent safety profile with no new safety signals. ASND stock rose 3.60% to $223.37 on the news.

Ascendis Pharma announced it will present clinical trial data from its rare endocrinology programs at ENDO 2026, including two oral presentations and three posters covering hypoparathyroidism, achondroplasia, and pediatric growth hormone deficiency. The presentations will showcase long-term safety and efficacy data for TransCon PTH and benefits of TransCon CNP alone and combined with TransCon hGH in children with achondroplasia.

Ascendis Pharma A/S announced plans to list its ordinary shares directly on Nasdaq effective April 20, 2026, with all outstanding American Depositary Shares (ADSs) to be exchanged on a 1:1 basis for ordinary shares. The company believes the direct listing will broaden global investment access, potentially facilitate inclusion in equity indexes, and enhance institutional ownership and trading liquidity.

The FDA has granted accelerated approval to YUVIWEL (navepegritide), developed by Ascendis Pharma, as the first and only once-weekly treatment for children aged 2 and older with achondroplasia. The drug provides continuous systemic exposure to CNP over the weekly dosing interval and is expected to be commercially available in early Q2 2026. The approval was based on improved annualized growth velocity data from three randomized clinical trials.

BridgeBio Pharma announced positive Phase 3 trial results for infigratinib in treating achondroplasia (dwarfism) in children, showing superior annualized height velocity compared to placebo. The company plans to submit FDA and regulatory applications in the second half of 2026. The stock surged 6.92% to $78.41, nearing its 52-week high.

Ascendis Pharma announced strong 2025 financial results with YORVIPATH generating €477 million and SKYTROFA generating €206 million in revenue. The company expects TransCon CNP approval in the U.S. by February 2026 and outlined expansion plans across multiple product candidates and geographic markets. Strategic collaborations with Novo Nordisk, Eyconis, VISEN Pharmaceuticals, and Teijin Limited are advancing, with a planned $120 million share repurchase program for 2026.

Ascendis Pharma received notification from the FDA extending the PDUFA target action date for TransCon CNP by three months to February 28, 2026, after submitting additional information for their New Drug Application for treating children with achondroplasia.